DBT引导与超声引导活检非钙化乳腺病变的比较
回顾性比较数字乳腺断层摄影引导活检(DBT-BX)与超声引导活检(US-BX)对非钙化乳腺病变的影像特征与活检结果。DBT-BX组的恶性阳性预测值(PPV3)为33.5%,低于US-BX组的47.7%。超声引导活检对可见超声对应病灶的非钙化病变PPV3更高且定位夹移位率更低。
要点
- 超声可见的非钙化乳腺病变优先考虑US-BX,其PPV3更高且定位夹移位率更低。
- 无可明确超声对应病灶的可疑不对称影与结构扭曲,DBT-BX仍有临床可接受的PPV3。
- DBT-BX后需注意定位夹移位率较高(10.3%),报告时应关注定位准确性。
核心结论
- US-BX对非钙化乳腺病变的PPV3为47.7%,高于DBT-BX的33.5%(p<0.001)。
- US-BX定位夹移位率为1.6%,显著低于DBT-BX的10.3%(p<0.001)。
- DBT-BX对可疑不对称影(PPV3 28.4%)和结构扭曲(PPV3 31.1%)保持临床可接受的恶性阳性预测值。
研究设计与样本
- 研究类型为符合HIPAA的回顾性研究,连续纳入2016年4月1日至2018年3月31日接受DBT-BX或US-BX的患者。
- 通过放射信息系统识别患者,患者需有乳腺X线可见的非钙化病变且接受过靶向超声评估。
- DBT-BX组纳入215例患者(224次活检,平均年龄58.7±12.2岁),US-BX组纳入907例患者(949次活检,平均年龄57.4±14.5岁)。
- 连续变量采用Mann-Whitney U检验,分类变量采用Pearson卡方检验进行组间比较。
关键影像表现/征象
- DBT-BX靶向的病变类型为不对称影占45.5%、结构扭曲占33.0%、肿块占21.4%。
- US-BX主要靶向超声对应病灶中的肿块占57.1%、不对称影占39.7%。
- DBT-BX在非致密乳腺中更为常见(65.6% vs 50.2%,p<0.001)。
诊断标准与关键数值
- DBT-BX的PPV3为33.5%,US-BX为47.7%,差异有统计学意义(p<0.001)。
- 不对称影的PPV3:DBT-BX为28.4%,US-BX为49.9%(p<0.001)。
- 结构扭曲的PPV3:DBT-BX为31.1%,US-BX为73.3%(p=0.001)。
临床应用与阅片要点
- 非钙化乳腺病变若超声可见明确对应病灶,应优先选择US-BX以获得更高诊断效能。
- 对超声无明确对应病灶的可疑不对称影和结构扭曲,DBT-BX仍是合适的活检方式。
- DBT-BX后需关注定位夹移位风险,应在报告中评估定位夹位置准确性。
局限性
- 回顾性研究设计可能存在选择偏倚。
- 单中心研究,结果外推需谨慎。
- 原文未报告设备型号与序列参数等可能影响对比的细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVE: To compare the imaging characteristics and biopsy outcomes of noncalcified mammographic findings that underwent digital breast tomosynthesis-guided biopsy (DBT-BX) versus ultrasound-guided biopsy (US-BX).
MATERIALS AND METHODS: In this HIPAA-compliant retrospective study, consecutive patients who underwent DBT-BX or US-BX between 4/1/2016 and 3/31/2018, were identified through the Radiology Information System. Eligible patients had a mammographically visible, noncalcified lesion and targeted US evaluation. Patient demographics, breast density, lesion type, BI-RADS category, clip placement accuracy, and pathology results were recorded. Statistical comparisons between groups were performed using the Mann-Whitney U test for continuous variables and Pearson's chi-squared test for categorical variables.
RESULTS: The DBT-BX group included 215 patients (224 biopsies; mean age, 58.7±12.2 years), and the US-BX group included 907 patients (949 biopsies; mean age, 57.4±14.5 years). DBT-BX targeted asymmetries (45.5%), architectural distortions (33.0%), and masses (21.4%), while US-BX targeted primarily sonographic correlates of masses (57.1%) and asymmetries (39.7%). DBT-BX was more frequent in non-dense breasts (65.6% vs 50.2%; p<0.001) and demonstrated higher clip displacement rates (10.3% vs 1.6%; p < 0.001). The positive predictive value for malignancy (PPV3) was significantly lower for DBT-BX (33.5%) compared with US-BX (47.7%; p<0.001), particularly for asymmetries (28.4% vs 49.9%; p<0.001) and architectural distortions (31.1% vs 73.3%; p=0.001).
CONCLUSION: US-BX of noncalcified breast lesions demonstrated higher PPV3 and lower clip displacement rates compared with DBT-BX. DBT-BX of suspicious asymmetries and distortions, however, maintained clinically relevant PPV3 and remains appropriate when no definite US correlate is present.
引用
- Baikpour, Lamb, Magara, et al. Comparison of Digital Breast Tomosynthesis-Guided Biopsy versus Ultrasound-Guided Biopsy of Non-Calcified Breast Lesions. Acad Radiol. 2026. PMID: 42431795. doi:10.1016/j.acra.2026.06.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。